Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
PPD: Gains 10% This Month From Q2 Results On 8.16% FCF Margin, But Valuation Remains Behind
03:52pm, Thursday, 13'th Aug 2020
PPD beats the Street by $84.5 million on revenues, but misses EPS by $0.15. FCF Margin of 8.16% of turnover on FCF position of $339 million exiting the second quarter.
Genomic Medicine: Summer 2020 Update
09:36am, Thursday, 13'th Aug 2020
FDA approvals, new guidance statements, and RMAT requests all show the pace of genomics is accelerating.
Beam Therapeutics Announces First Development Candidates for Sickle Cell Disease and Reports Second Quarter 2020 Results
10:30am, Wednesday, 12'th Aug 2020
BEAM-101 and BEAM-102 Named as Development Candidates Targeting Distinct Approaches to Treating Sickle Cell Disease Lease Agreement Signed to Build In-house Manufacturing Facility Dedicated to Produc
Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results
12:00am, Thursday, 06'th Aug 2020
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to
What Is The Ownership Structure Like For Beam Therapeutics Inc. (NASDAQ:BEAM)?
11:15am, Tuesday, 04'th Aug 2020
A look at the shareholders of Beam Therapeutics Inc. (NASDAQ:BEAM) can tell us which group is most powerful. Generally...
Beam Therapeutics to Participate in Upcoming Investor Conferences
10:30am, Thursday, 30'th Jul 2020
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man
U.S. IPO Week Ahead: Tax Software Leads A Diverse 7-IPO Week
08:52am, Saturday, 25'th Jul 2020
Seven IPOs and one SPAC plan to raise $2.1 billion in the week ahead, led by tax software provider Vertex.
Magenta Therapeutics (Nasdaq: MGTA) and Beam Therapeutics (Nasdaq: BEAM) today announced a non-exclusive research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Ma
Beam Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference
10:30am, Tuesday, 26'th May 2020
CAMBRIDGE, Mass., May 26, 2020 -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced.
Beam Therapeutics Taking Novel Approach to Gene Therapy
10:21pm, Monday, 18'th May 2020
Company shares up substantially since early February IPO Continue reading...
Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering
05:40pm, Tuesday, 12'th May 2020
This week’s online annual meeting of the American Society for Gene and Cell Therapy will take place on the web.
Beam Therapeutics Reports Additional Data at ASGCT Annual Meeting and First Quarter 2020 Financial Results
10:30am, Tuesday, 12'th May 2020
Alpha-1 Antitrypsin Deficiency Program Demonstrates More than Four-Fold Increase in Circulating Levels of Functional Protein Following Durable Direct Correction In Vivo Novel.
Will Beam Therapeutics (NASDAQ:BEAM) Spend Its Cash Wisely?
02:25pm, Wednesday, 06'th May 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
CAMBRIDGE, Mass., April 28, 2020 -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced.
